Showing 1251-1260 of 9374 results for "".
A Growing Armamentarium for Psoriasis: How to Choose the Right Treatment for Each Patient
https://practicaldermatology.com/topics/psoriasis/a-growing-armamentarium-for-psoriasis-how-to-choose-the-right-treatment-for-each-patient/18214/Erin Boh, MD joins host Joshua Zeichner, MD in this edition of DermTube Journal Club to offer tips for navigating all the new and existing treatment options for patients with moderate to severe psoriasis. With so many effective options on the market, Dr. Boh says it's possible to find the best fit fDupixent, Juvéderm Vollure XC, Bavencio Approvals
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-dupixent-juv-derm-vollure-xc-bavencio-approvals/18698/The FDA has approved Regeneron's injectable Dupixent (dupilumab) to treat adults with moderate-to-severe eczema. It will be marketed by Regeneron and Sanofi Genzyme in the US. Allergan's Juvéderm Vollure XC has received FDA approval based on a pivotal clinical trial in which 59 percent of subjects sPsO Many Options: The Expanded Psoriasis Landscape
https://practicaldermatology.com/topics/psoriasis/pso-many-options-the-expanded-psoriasis-landscape/18749/By Jeffrey Weinberg, MD and Seemal R. Desai, MDWith many new therapies coming out in oral, topical, and biologic forms, there are fewer unmet needs in psoriasis management now than ever before. Dr. Weinberg navigates the therapeutic landscape.Telemedicine and Access, Inappropriate Antibiotics, Industry Growth
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-telemedicine-and-access-inappropriate-antibiotics-industry-growth/18602/New research published online in JAMA Dermatology suggests that teledermatology improves access to care. Experts predict continued growth of telemedicine in dermatology. New estimates suggest that 30% of antibiotic prescriptions may be inappropriate. Dermatologists warn against antibiotic misuse andWhen and How to Use Ancillary Testing
https://practicaldermatology.com/programs/practical-dermatology-updates-in-skin-cancer/when-and-how-to-use-ancillary-testing/35598/Hadas Skupsky, MD, a board-certified dermatologist and dermatopathologist, discusses when a dermatopathologist decides to use ancillary testing for melanoma, how that impacts final diagnosis, and how it can guide treatment decisions.Noah Worcester 2024: AAD President Dr. Desai on the AAD
https://practicaldermatology.com/conferences/noah-worcester-2024/noah-worcester-2024-dr-desai-aad/24589/Seemal Desai, MD, FAAD, president of the American Academy of Dermatology, summarizes his AAD update presentation at the 2024 Noah Worcester Dermatological Society meeting.DermWire TV: Merz Reorganizes; Amzeeq Approved; Restoration Merges with Venus Concept
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-merz-reorganizes-amzeeq-approved-restoration-merges-with-venus-concept/19694/Bob Rhatigan, newly appointed Global Chief Executive Officer of Merz Aesthetics, speaks about Merz reorganization. Amzeeq topical foam (Foamix Pharmaceuticals) approved for inflammatory, non-nodular, moderate to severe acne vulgaris in adults and pediatric patients 9 years of age and older. FDA acGalderma's Differin Goes OTC, CoolSculpting Approved for Upper Arms, ZO Skin Acquires ReFissa
https://practicaldermatology.com/series/dermwire-tv/galderma-s-differin-goes-otc-coolsculpting-approved-for-upper-arms-zo-skin-acquires-refissa/18549/Galderma's Differin Gel formulation of adapalene 0.1% is now available over the counter at major retail and drug stores in the US. ZELTIQ® Aesthetics' CoolSculpting is now FDA-cleared for fat reduction in the upper arms. ZO Skin Health has acquired the worldwide rights to ReFissa from Suneva MedicalIn-Office Photos Are an Indispensable Benefit According to Joel Schlessinger MD
https://practicaldermatology.com/topics/practice-management/in-office-photos-are-an-indispensable-benefit-according-to-joel-schlessinger-md-/19221/One way dermatologists can chart the success of their patients is by taking photos before, after and during their treatments. For over 20 years, Joel Schlessinger MD has incorporated photos of his patients into his practice. In this video, he describes the benefits of this technique. Joel SchlessVitiligo Update: Pathogenesis, Therapies, and Integrative Approaches
https://practicaldermatology.com/issues/may-june-2025/vitiligo-update-pathogenesis-therapies-and-integrative-approaches/35920/Vitiligo is a chronic autoimmune condition characterized by depigmented white patches due to melanocyte destruction, attributed to genetic factors and environmental triggers.